Shares of Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) dropped 8.8% during trading on Wednesday . The company traded as low as GBX 192 ($2.53) and last traded at GBX 197 ($2.60). Approximately 102,171 shares were traded during trading, an increase of 79% from the average daily volume of 57,005 shares. The stock had previously closed at GBX 216 ($2.85).
Faron Pharmaceuticals Oy Stock Performance
The company has a debt-to-equity ratio of 121.51, a current ratio of 0.59 and a quick ratio of 1.09. The stock has a market capitalization of £214.47 million, a PE ratio of -597.06 and a beta of 0.35. The firm has a fifty day moving average price of GBX 147.13 and a two-hundred day moving average price of GBX 149.95.
Faron Pharmaceuticals Oy Company Profile
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation.
Read More
- Five stocks we like better than Faron Pharmaceuticals Oy
- 3 Best Fintech Stocks for a Portfolio Boost
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- Top Biotech Stocks: Exploring Innovation Opportunities
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- Want to Profit on the Downtrend? Downtrends, Explained.
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
